BlackRock
VIRX

BlackRock’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

BlackRock’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-234,846
Closed -$37.8K – 5566
2024
Q4 		$37.8K Hold
234,846
– – ﹤0.01% 5006
2024
Q3 		$54.3K Sell
234,846
-38,451
-14% -$14.1K ﹤0.01% 4794
2024
Q2 		$149K Sell
273,297
-30,683
-10% -$24.2K ﹤0.01% 4610
2024
Q1 		$310K Sell
303,980
-1,672
-0.5% -$1.22K ﹤0.01% 4494
2023
Q4 		$174K Sell
305,652
-836
-0.3% -$513 ﹤0.01% 4673
2023
Q3 		$319K Sell
306,488
-153,747
-33% -$209K ﹤0.01% 4553
2023
Q2 		$649K Buy
460,235
+12,434
+3% +$17.8K ﹤0.01% 4414
2023
Q1 		$712K Sell
447,801
-274
-0.1% -$498 ﹤0.01% 4445
2022
Q4 		$654K Sell
448,075
-214,525
-32% -$627K ﹤0.01% 4534
2022
Q3 		$2.83M Buy
662,600
+120,169
+22% +$509K ﹤0.01% 4014
2022
Q2 		$2.1M Sell
542,431
-1,770,477
-77% -$5.04M ﹤0.01% 4237
2022
Q1 		$11M Sell
2,312,908
-56,010
-2% -$169K ﹤0.01% 3526
2021
Q4 		$8.65M Buy
2,368,918
+283,870
+14% +$1.51M ﹤0.01% 3762
2021
Q3 		$16.7M Buy
2,085,048
+23,877
+1% +$235K ﹤0.01% 3399
2021
Q2 		$23.4M Buy
2,061,171
+1,874,846
+1,006% +$18.8M ﹤0.01% 3207
2021
Q1 		$1.72M Buy
186,325
+127,420
+216% +$1.33M ﹤0.01% 4333
2020
Q4 		$411K Hold
58,905
– – ﹤0.01% 4376
2020
Q3 		$258K Hold
58,905
– – ﹤0.01% 4363
2020
Q2 		$543K Sell
58,905
-6,529
-10% -$98.4K ﹤0.01% 4192
2020
Q1 		$950K Buy
65,434
+32,201
+97% +$699K ﹤0.01% 3886
2019
Q4 		$393K Buy
33,233
+11,117
+50% +$186K ﹤0.01% 4201
2019
Q3 		$557K Sell
22,116
-257
-1% -$7.42K ﹤0.01% 4141
2019
Q2 		$569K Buy
22,373
+16,112
+257% +$623K ﹤0.01% 4162
2019
Q1 		$266K Buy
6,261
+1,339
+27% +$30.3K ﹤0.01% 4202
2018
Q4 		$72K Sell
4,922
-32
-0.6% -$1.31K ﹤0.01% 4414
2018
Q3 		$347K Buy
4,954
+113
+2% +$8.58K ﹤0.01% 4205
2018
Q2 		$359K Buy
4,841
+566
+13% +$50.4K ﹤0.01% 4180
2018
Q1 		$408K Buy
4,275
+544
+15% +$93.3K ﹤0.01% 4080
2017
Q4 		$482K Buy
3,731
+325
+10% +$30.5K ﹤0.01% 4058
2017
Q3 		$232K Sell
3,406
-65
-2% -$5.31K ﹤0.01% 4197
2017
Q2 		$328K Buy
3,471
+1,113
+47% +$128K ﹤0.01% 4125
2017
Q1 		$339K Buy
+2,358
New +$337K ﹤0.01% 4072
2015
Q2 		– Sell
-6
Closed -$3K – 3281
2015
Q1 		$3K Hold
6
– – ﹤0.01% 3104
2014
Q4 		$3K Hold
6
– – ﹤0.01% 3131
2014
Q3 		$9K Hold
6
– – ﹤0.01% 2811
2014
Q2 		$8K Buy
6
+1
+20% +$1.16K ﹤0.01% 2948
2014
Q1 		$6K Hold
5
– – ﹤0.01% 3016
2013
Q4 		$5K Hold
5
– – ﹤0.01% 3054
2013
Q3 		$5K Hold
5
– – ﹤0.01% 3003
2013
Q2 		$5K Buy
+5
New +$5.57K ﹤0.01% 3036

Other funds holding VIRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

BlackRock's VIRX Position: Q1 2025 in Review

BlackRock sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 234,846 shares — an estimated $37.8K sold.

BlackRock first reported a position in VIRX in Q2 2013 and held it in 40 quarters. The position peaked at $23.4M in Q2 2021. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • BlackRock reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • BlackRock sold 234,846 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $37.8K.
  • BlackRock first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 40 quarters.
  • BlackRock's Viracta Therapeutics, Inc. Common Stock position peaked at $23.4M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on BlackRock's 13F filing for Q1 2025, filed 2 May 2025.